Inhibition of GTPase KRAS^G12D: a review of patent literature

References

• Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017;170(1):17–33. doi: 10.1016/j.cell.2017.06.009
   PubMed Web of Science ®Google Scholar
• Prior IA, Lewis PD, Mattos C. A comprehensive survey of RAS mutations in cancer. Cancer Res. 2012;72(10):2457–2467. doi: 10.1158/0008-5472.CAN-11-2612
   PubMed Web of Science ®Google Scholar
• Punekar SR, Velcheti V, Neel BG, et al. The current state of the art and future trends in RAS-targeted cancer therapies. Nat Rev Clin Oncol. 2022;19(10):637–655. doi: 10.1038/s41571-022-00671-9
   PubMed Web of Science ®Google Scholar
• Hofmann MH, Gerlach D, Misale S, et al. Expanding the reach of precision oncology by drugging all KRAS mutants. Cancer Discov. 2022;12(4):924–937. doi: 10.1158/2159-8290.CD-21-1331
   PubMed Web of Science ®Google Scholar
• Lu S, Jang H, Gu S, et al. Drugging RAS GTPase: a comprehensive mechanistic and signaling structural view. Chem Soc Rev. 2016;45(18):4929–4952. doi: 10.1039/C5CS00911A
   PubMed Web of Science ®Google Scholar
• Bos JL, Rehmann H, Wittinghofer A. GEFs and GAPs: critical elements in the control of small G proteins. Cell. 2007;129(5):865–877. doi: 10.1016/j.cell.2007.05.018
   PubMed Web of Science ®Google Scholar
• Drosten M, Barbacid M. Targeting the MAPK pathway in KRAS-driven tumors. Cancer Cell. 2020;37(4):543–550. doi: 10.1016/j.ccell.2020.03.013
   PubMed Web of Science ®Google Scholar
• Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol. 2018;15(5):273–291. doi: 10.1038/nrclinonc.2018.28
   PubMed Web of Science ®Google Scholar
• Lim SM, Westover KD, Ficarro SB, et al. Therapeutic targeting of oncogenic K-RAS by a covalent catalytic site inhibitor. Angew Chem Int Ed. 2014;53(1):199–204. doi: 10.1002/anie.201307387
   PubMed Web of Science ®Google Scholar
• Hunter JC, Gurbani D, Ficarro SB, et al. In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-RAS G12C. Proc Natl Acad Sci USA. 2014;111(24):8895–8900. doi: 10.1073/pnas.1404639111
   PubMed Web of Science ®Google Scholar
• Muller MP, Jeganathan S, Heidrich A, et al. Nucleotide based covalent inhibitors of KRAS can only be efficient in vivo if they bind reversibly with GTP-like affinity. Sci Rep. 2017;7(1):3687. doi: 10.1038/s41598-017-03973-6
   PubMedGoogle Scholar
• Cox AD, Fesik SW, Kimmelman AC, et al. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13(11):828–851. doi: 10.1038/nrd4389
   PubMed Web of Science ®Google Scholar
• Ostrem JM, Shokat KM. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat Rev Drug Discov. 2016;15(11):771–785. doi: 10.1038/nrd.2016.139
   PubMed Web of Science ®Google Scholar
• Ostrem JM, Peters U, Sos ML, et al. K-RAS(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503(7477):548–551. doi: 10.1038/nature12796
   PubMed Web of Science ®Google Scholar
• Wang X, Allen S, Blake JF, et al. Identification of MRTX1133, a noncovalent, potent, and selective KRAS(G12D) inhibitor. J Med Chem. 2022;65(4):3123–3133. doi: 10.1021/acs.jmedchem.1c01688.
   PubMedGoogle Scholar
• Hallin J, Bowcut V, Calinisan A, et al. Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor. Nat Med. 2022;28(10):2171–2182. doi: 10.1038/s41591-022-02007-7
   PubMed Web of Science ®Google Scholar
• Mahadevan KK, McAndrews KM, LeBleu VS, et al. KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Cancer Cell. 2023;41(9):1606–1620. doi: 10.1016/j.ccell.2023.07.002
   PubMed Web of Science ®Google Scholar
• Bannoura SF, Khan HY, Azmi AS. KRAS G12D targeted therapies for pancreatic cancer: has the fortress been conquered? Front Oncol. 2022;12:1013902. doi: 10.3389/fonc.2022.1013902
   PubMed Web of Science ®Google Scholar
• Mao Z, Xiao H, Shen P, et al. KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge. Cell Discov. 2022;8(1):5. doi: 10.1038/s41421-021-00368-w
   PubMed Web of Science ®Google Scholar
• Mirati Therapeutics Inc. Array BioPharma Inc. Preparation of 4-(3,8-diazabicyclo[3.2.1]octan-3-yl)pyrido[4,3-d]pyrimidines as KRAS G12D inhibitors and their preparation. WO2022015375. 2022.
   Google Scholar
• Mirati Therapeutics Inc; Array Biopharma Inc. Preparation of substituted pyrido[4,3-d]pyrimidin-4-amines as KRAS G12D inhibitors. WO2022031678. 2022.
   Google Scholar
• Mirati Therapeutics Inc. Preparation of azaquinazoline pan-KRAS inhibitors. WO2022132200. 2022.
   Google Scholar
• Xiao X, Feng J, Ma J, et al. Design, synthesis, and pharmacological evaluation of multisubstituted pyrido[4,3-d]pyrimidine analogues bearing deuterated methylene linkers as potent KRAS G12D inhibitors. J Med Chem. 2023;66(22):15524–15549. doi: 10.1021/acs.jmedchem.3c01724
   PubMed Web of Science ®Google Scholar
• Silexon AI Technology Co Ltd. Preparation of deuterated compounds useful as KRAS G12D inhibitors. WO2022262838. 2022.
   Google Scholar
• Amgen Inc. Preparation of heterocyclic compounds for inhibiting KRAS G12D. WO2023018812. 2023.
   Google Scholar
• Beta Pharma Inc. Preparation of azabicycloctyl- and ethynylnaphthyl-substituted pyridopyrimidines and pyrimidopyrimidines as inhibitors of the KRAS oncoprotein G12D for potential use as antitumor agents. WO2023101928. 2023.
   Google Scholar
• InventisBio Co Ltd. Preparation of pyridopyrimidines and related heteroaryl compounds as mutant KRAS inhibitors for the treatment of cancers. WO2022042630. 2022.
   Google Scholar
• Ya Therapeutics Inc. Preparation and use of KRAS mutant protein inhibitor. WO2022193871. 2022.
   Google Scholar
• Shanghai Zion Pharma Co Ltd. Preparation of heterocycles as KRAS G12D inhibitors and uses thereof. WO2023284537. 2023.
   Google Scholar
• Jacobio Pharmaceuticals Co Ltd. Synthesis of fused ring heterocyclic KRAS G12D inhibitors as anticancer agents. WO2022188729. 2022.
   Google Scholar
• GenFleet Therapeutics (Shanghai) Inc; Zhejiang GenFleet Therapeutics Co Ltd. Pyrimidine-fused cyclic compounds as KRAS inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. WO2023030385. 2023.
   Google Scholar
• Shanghai Zion Pharma Co Ltd. Preparation of macrocyclic heterocyclic compounds as Kras G12D inhibitors useful in treatment of cancer and other diseases. WO2023001141. 2023.
   Google Scholar
• Jacobio Pharmaceuticals Co Ltd. Preparation of N-cyclopropylpyrido[4,3-d]pyrimidin-4-amine derivatives and related compounds as K-RAS mutant protein inhibitors. WO2023246777. 2023.
   Google Scholar
• Ya Therapeutics Inc. Preparation of aromatic compounds used as KRAS mutant protein inhibitors. CN117263959. 2023.
   Google Scholar
• Ji X, Li Y, Kong X, et al. Discovery of prodrug of MRTX1133 as an oral therapy for cancers with KRAS G12D mutation. ACS Omega. 2023;8(7):7211–7221. doi: 10.1021/acsomega.3c00329
   PubMedGoogle Scholar
• Hangzhou Innogate Pharma Co Ltd. Polycyclic compounds as KRAS G12D inhibitors. WO2023198078. 2023.
   Google Scholar
• Cheng H, Li P, Chen P, et al. Structure-based design and synthesis of potent and selective KRAS G12D inhibitors. ACS Med Chem Lett. 2023;14(10):1351–1357. doi: 10.1021/acsmedchemlett.3c00245
   PubMed Web of Science ®Google Scholar
• Amgen Inc. Preparation of 2-aminobenzothiazole compounds as antitumor agents. WO2022232332. 2022.
   Google Scholar
• InventisBio Co Ltd. Quinazoline compounds, preparation methods and uses thereof as inhibitors of KRAS G12D. WO2022002102. 2022.
   Google Scholar
• Erasca Inc. Preparation of selective KRAS inhibitors. WO2022221386. 2022.
   Google Scholar
• Jacobio Pharmaceuticals Co Ltd. Quinazoline derivatives as KRAS G12D inhibitors and their preparation. WO2022105859. 2022.
   Google Scholar
• Betta Pharmaceuticals Co Ltd. KRAS G12D inhibitor and applications thereof in medicine. WO2022194066. 2022.
   Google Scholar
• Mirati Therapeutics Inc. Preparation of the quinazoline pan-KRAS inhibitors. WO2023150284. 2023.
   Google Scholar
• Mirati Therapeutics Inc; Array Biopharma Inc. Quinazoline derivatives as KRAS G12D inhibitors and their preparation. WO2022098625. 2022.
   Google Scholar
• Shanghai Apeiron Therapeutics Company Limited. Heterocyclic compounds as KRAS G12D inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. WO2023138583. 2023.
   Google Scholar
• Reich HJ, Hondal RJ. Why nature chose selenium. ACS Chem Biol. 2016;11(4):821–841. doi: 10.1021/acschembio.6b00031
   PubMed Web of Science ®Google Scholar
• Jinan University Guangzhou. Salustier Biosciences Co Ltd. Preparation of selenium-containing heterocyclic compound for treatment of cancer. WO2023246903. 2023.
   Google Scholar
• Erasca Inc. Tricyclic piperazine compounds as KRAS G12D inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. WO2022266069. 2022.
   Google Scholar
• Shanghai De Novo Pharmatech Co Ltd. Preparation of KRAS G12D inhibitor as antitumor agent. CN115557974. 2023.
   Google Scholar
• Genentech Inc. Preparation of tetracyclic oxazepine compounds and uses thereof. WO2022173678. 2022.
   Google Scholar
• Hangzhou Polymed Biopharmaceuticals Inc. Six- and six-membered compound, preparation method, pharmaceutical composition, and application. WO2023198191. 2023.
   Google Scholar
• Zhejiang Hisun Pharmaceutical Co Ltd. Hisun Accuray Therapeutics Co Ltd. Preparation of tricyclic derivative as KRAS inhibitor. CN115124524. 2022.
   Google Scholar
• Zhejiang Hisun Pharmaceutical Co Ltd. Shanghai Aryl Pharmatech Co Ltd. Heterocyclic derivative, and preparation method therefor and use thereof in medicine. WO2022206723. 2022.
   Google Scholar
• Shanghai Kechow Pharma Inc. Heterocyclic compounds as KRAS inhibitor, preparation therefor and use thereof in treatment. WO2022247760. 2022.
   Google Scholar
• Zhejiang Hisun Pharmaceutical Co Ltd. Hisun Accuray Therapeutics Co Ltd. Tetracyclic derivative, and preparation method therefor and medical use thereof. CN115124533. 2022.
   Google Scholar
• Zhejiang Hisun Pharmaceutical Co Ltd. Hisun Accuray Therapeutics Co Ltd. Preparation of fused tricyclic derivatives as KRAS G12D inhibitor and its application in treatment of cancer. CN116332938. 2023.
   Google Scholar
• Foshan Chenkang Biotechnology Co Ltd. Preparation of thienopyrimidine compound as anti-cancer drugs. CN114989195. 2022.
   Google Scholar
• Luca C, Rebecca H, Simon AD, et al. Developing small molecules that inhibit k-ras/gtp binding based on new affinity measurements. bioRxiv. 2020:2020–2007.
   Google Scholar
• Grant BJ, Lukman S, Hocker HJ, et al. Novel allosteric sites on RAS for lead generation. PLOS One. 2011;6(10):e25711. doi: 10.1371/journal.pone.0025711
   PubMed Web of Science ®Google Scholar
• Mirati Therapeutics Inc; Array Biopharma Inc. Preparation of diazobicyclooctanyl tetrahydropyridopyrimidines and related heterocycles as KRAS G12D inhibitors for the treatment of cancers. WO2022066646. 2022.
   Google Scholar
• Mirati Therapeutics, Inc. Tetrahydropyridopyrimidines as pan-KRAS inhibitors and their preparation. WO2022133038. 2022.
   Google Scholar
• Jiangsu Hengrui Pharmaceuticals Co Ltd. Preparation of (diazabicyclo[3.2.1]octanyl)((fluorohexahydropyrrolizinyl)methoxy)(naphthyl)dihydropyrido[3,4-d]pyrimidines as antitumor agent. CN115368383. 2022.
   Google Scholar
• Taiho Pharmaceutical Co Ltd. Pyrrolopyrimidines and related compounds as small molecule inhibitors of KRAS mutated proteins and their preparation. WO2022250170. 2022.
   Google Scholar
• Jiangsu Hengrui Pharmaceuticals Co Ltd. Preparation of (diazabicyclo[3.2.1]octanyl)((fluorohexahydropyrrolizinyl)methoxy)(naphthyl)tetrahydroquinazolines as antitumor agent. CN115385937. 2022.
   Google Scholar
• Medshine Discovery Inc. Preparation of pyrimidopyran compounds as KRAS G12D inhibitors. WO2022161443. 2022.
   Google Scholar
• Lynk Pharmaceuticals Co Ltd. Preparation of nitrogen-containing heterocyclic compound and application thereof. WO2023125627. 2023.
   Google Scholar
• Lovering F, Bikker J, Humblet C. Escape from flatland: increasing saturation as an approach to improving clinical success. J Med Chem. 2009;52(21):6752–6756. doi: 10.1021/jm901241e
   PubMed Web of Science ®Google Scholar
• 1200 Pharma LLC. Preparation of spiro[naphthalene-quinazoline] derivatives as KRAS G12D inhibitors and uses thereof. WO2022240971. 2022.
   Google Scholar
• Lorthiois E, Gerspacher M, Beyer KS, et al. JDQ443, a structurally novel, pyrazole-based, covalent inhibitor of KRAS G12C for the treatment of solid tumors. J Med Chem. 2022;65(24):16173–16203. doi: 10.1021/acs.jmedchem.2c01438
   PubMed Web of Science ®Google Scholar
• Taiho Pharmaceutical Co Ltd. Imidazole derivatives as KRAS G12D protein inhibitors and their preparation. WO2021215544. 2021.
   Google Scholar
• Kessler D, Gmachl M, Mantoulidis A, et al. Drugging an undruggable pocket on KRAS. Proc Natl Acad Sci USA. 2019;116(32):15823–15829. doi: 10.1073/pnas.1904529116
   PubMed Web of Science ®Google Scholar
• Bröker J, Waterson AG, Smethurst C, et al. Fragment optimization of reversible binding to the switch ii pocket on KRAS leads to a potent, in vivo active KRAS G12C inhibitor. J Med Chem. 2022;65(21):14614–14629. doi: 10.1021/acs.jmedchem.2c01120
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim International GmbH; Vanderbilt University. KRAS degrading compounds comprising annulated 2-amino-3-cyanothiophenes and their preparation. WO2023099620. 2023.
   Google Scholar
• Kim D, Herdeis L, Rudolph D, et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature. 2023;619(7968):160–166. doi: 10.1038/s41586-023-06123-3
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim International GmbH; Vanderbilt University. Annulated 2-amino-3-cyanothiophenes and derivatives for the treatment of cancer and their preparation. WO2023099623. 2023.
   Google Scholar
• Boehringer Ingelheim International GmbH; Vanderbilt University. Annulated 2-amino-3-cyanothiophenes and derivatives for the treatment of cancer and their preparation. WO2023099608. 2023.
   Google Scholar
• Boehringer Ingelheim International GmbH; Vanderbilt University. Annulated 2-amino-3-cyanothiophenes and derivatives for the treatment of cancer and their preparation. WO2023099612. 2023.
   Google Scholar
• Philippe GJB, Craik DJ, Henriques ST. Converting peptides into drugs targeting intracellular protein–protein interactions. Drug Discov Today. 2021;26(6):1521–1531. doi: 10.1016/j.drudis.2021.01.022
   PubMed Web of Science ®Google Scholar
• Tanada M, Tamiya M, Matsuo A, et al. Development of orally bioavailable peptides targeting an intracellular protein: from a hit to a clinical KRAS inhibitor. J Am Chem Soc. 2023;145(30):16610–16620. doi: 10.1021/jacs.3c03886
   PubMed Web of Science ®Google Scholar
• Bondeson DP, Mares A, Smith IED, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol. 2015;11(8):611–617. doi: 10.1038/nchembio.1858
   PubMed Web of Science ®Google Scholar
• Schulze CJ, Seamon KJ, Zhao Y, et al. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. Science. 2023;381(6659):794–799. doi: 10.1126/science.adg9652
   PubMed Web of Science ®Google Scholar
• Revolution Medicines Inc. Indole derivatives as RAS inhibitors in the treatment of cancer and their preparation. WO2022060836. 2022.
   Google Scholar
• Zeng M, Xiong Y, Safaee N, et al. Exploring targeted degradation strategy for oncogenic KRAS G12C. Cell Chem Biol. 2020;27(1):19–31. doi: 10.1016/j.chembiol.2019.12.006
   PubMed Web of Science ®Google Scholar
• Bond MJ, Chu L, Nalawansha DA, et al. Targeted degradation of oncogenic KRAS G12C by VHL-recruiting PROTACs. ACS Cent Sci. 2020;6(8):1367–1375. doi: 10.1021/acscentsci.0c00411
   PubMed Web of Science ®Google Scholar
• Yang F, Wen Y, Wang C, et al. Efficient targeted oncogenic KRAS G12C degradation via first reversible-covalent PROTAC. Eur J Med Chem. 2022;230:114088. doi: 10.1016/j.ejmech.2021.114088
   PubMed Web of Science ®Google Scholar
• Zhou C, Fan Z, Gu Y, et al. Design, synthesis, and biological evaluation of potent and selective protac degraders of oncogenic KRAS G12D. J Med Chem. 2024;67(2):1147–1167. doi: 10.1021/acs.jmedchem.3c01622
   PubMed Web of Science ®Google Scholar
• Shanghai Pharmaceuticals Holding Co Ltd. Compound targeting protein modulator and application thereof. CN115260158. 2022.
   Google Scholar
• Ranok Therapeutics (Hangzhou) Co Ltd. Preparation of pyridopyrimidines and their methods and compositions for targeted protein degradation. WO2023081476. 2023.
   Google Scholar
• Arvinas Operations Inc. Preparation of bifunctional compounds and methods for the targeted degradation of KRAS. WO2023141570. 2023.
   Google Scholar
• Han X, Sun Y. Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy. Cell Rep Phys Sci. 2022;3(10):101062. doi: 10.1016/j.xcrp.2022.101062
   Google Scholar
• Imaizumi T, Shimada I, Satake Y, et al. Discovery of ASP6918, a KRAS G12C inhibitor: synthesis and structure–activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors. Biorg Med Chem. 2024;98:117581. doi: 10.1016/j.bmc.2023.117581
   PubMed Web of Science ®Google Scholar
• Astellas Pharma Inc. Preparation of L-prolinamide-linked heterocyclic compounds for inducing degradation of G12D mutant KRAS protein. WO2023171781. 2023.
   Google Scholar
• Erasca Inc. KRAS inhibitorconjugates. WO2022266206 2022.
   Google Scholar
• BeiGene Ltd. Preparation of bridged compounds as KRAS G12D inhibitors and degraders useful in treatment and prevention of diseases. WO2022148421. 2022.
   Google Scholar
• Johannes P, William F, Andreas G, et al. Targeting cancer with small molecule pan-KRAS degraders. bioRxiv. 2023:2023–2010.
   Google Scholar
• Mahadevan KK, LeBleu VS, Ramirez EV, et al. Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells. Dev Cell. 2023;58(17):1562–1577. doi: 10.1016/j.devcel.2023.07.025
   PubMed Web of Science ®Google Scholar
• Dunnett-Kane V, Nicola P, Blackhall F, et al. Mechanisms of resistance to KRAS G12C inhibitors. Cancers (Basel). 2021;13(1):151. doi: 10.3390/cancers13010151
   PubMed Web of Science ®Google Scholar
• Kim MJ, Lee SJ, Ryu JH, et al. Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment. J Controlled Release. 2020;318:98–108. doi: 10.1016/j.jconrel.2019.12.019
   PubMed Web of Science ®Google Scholar
• Gulay KCM, Zhang X, Pantazopoulou V, et al. Dual inhibition of KRAS G12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma. Cancer Res. 2023;83(18):3001–3012. doi: 10.1158/0008-5472.CAN-23-1313
   PubMed Web of Science ®Google Scholar
• Baltanás FC, García-Navas R, Rodríguez-Ramos P, et al. Critical requirement of SOS1 for tumor development and microenvironment modulation in KRAS G12D-driven lung adenocarcinoma. Nat Commun. 2023;14(1):5856. doi: 10.1038/s41467-023-41583-1
   PubMed Web of Science ®Google Scholar
• Ryan MB, Fece de la Cruz F, Phat S, et al. Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS G12C inhibition. Clin Cancer Res. 2020;26(7):1633–1643. doi: 10.1158/1078-0432.CCR-19-3523
   PubMed Web of Science ®Google Scholar
• Mirati Therapeutics Inc. Combinations of KRAS protein inhibitors and SHP-2 inhibitors for treating cancer. WO2023059598. 2023.
   Google Scholar
• Khan HY, Aboukameel A, Uddin MH, et al. Abstract B077: KRASG12D inhibitor MRTX1133 synergizes with the next generation nuclear transport protein inhibitor eltanexor resulting in enhanced antitumor activity against pancreatic ductal adenocarcinoma. Cancer Res. 2024;84(2_Supplement):B077. doi: 10.1158/1538-7445.PANCA2023-B077
   Web of Science ®Google Scholar
• Pant S, Wainberg ZA, Weekes CD, et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat Med. 2024;30(2):531–542. doi: 10.1038/s41591-023-02760-3
   PubMed Web of Science ®Google Scholar
• Yu Z, He X, Wang R, et al. Simultaneous covalent modification of K-RAS(G12D) and K-RAS(G12C) with tunable oxirane electrophiles. J Am Chem Soc. 2023;145(37):20403–20411. doi: 10.1021/jacs.3c05899
   PubMed Web of Science ®Google Scholar